Cross-reactive coronavirus antibodies might not be cross-neutralizing

NewsGuard 100/100 Score

In a recent study posted to Research Square* preprint server, researchers reported that cross-reactive antibodies against coronaviruses (CoVs) might not cross-neutralize all CoVs.

Several studies have reported that, in binding and pseudovirus neutralization assays, exposure to CoVs or vaccination against them induces cross-reactive antibodies, including against the latest severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2). However, plasma from the pre-coronavirus disease 2019 (COVID-19) pandemic times could not neutralize live SARS-CoV-2.

Occasionally, the results of binding assays are referred to as neutralizing, but the relevance of binding assays is different from the neutralization of viruses by antibodies. For example, recent studies have reported that antibodies against SARS-CoV-2 could bind to seasonal CoVs, and it remains unclear whether these cross-reactive antibodies could neutralize the seasonal CoVs.

Study: Function matters: Coronavirus cross-binding antibodies do not cross-neutralize. Image Credit: Andrii Vodolazhskyi / ShutterstockStudy: Function matters: Coronavirus cross-binding antibodies do not cross-neutralize. Image Credit: Andrii Vodolazhskyi / Shutterstock

This news article was a review of a preliminary scientific report that had not undergone peer-review at the time of publication. Since its initial publication, the scientific report has now been peer reviewed and accepted for publication in a Scientific Journal. Links to the preliminary and peer-reviewed reports are available in the Sources section at the bottom of this article. View Sources

About the study

In the present study, researchers evaluated whether SARS-CoV-2 infection or vaccination-induced immune responses could cross-neutralize seasonal CoVs.

Antibody concentrates were prepared from the plasma of SARS-CoV-2-naïve donors (pre-pandemic), plasma from COVID-19-recovered donors (post-COVID), or vaccinated donors (pandemic). The collected plasma specimens were used to prepare immunoglobulin (IG) lots through a licensed process, which were then tested to neutralize SARS-CoV-2 and human CoVs (HCoVs) such as OC43 and NL63. The pre-pandemic and pandemic IG were prepared from the plasma of donors in the United States (US) from April to June 2020 and July to September 2021, respectively. Post-COVID IG was obtained from donors from Austria or the US.

A previously established protocol determined neutralizing antibody (nAb) titers against SARS-CoV-2. Similarly, nAb titers against both HCoVs were evaluated. In brief, the serially diluted (IG) specimens were incubated with either HCoV at 103 median tissue culture infectious dose (TCID50) per milliliter (ml). The cytopathic effect was studied after 9 – 11 days of incubation of HCoV-NL63 on LLC-MK2 cells and 6 – 8 days of HCoV-OC43 on MRC-5 cells. The resultant 50% virus neutralization (µNT50) was estimated using the Spearman-Karber method and subsequently normalized to an internal control. The nAb potency was compared between pre-pandemic, pandemic, and post-COVID IG lots.

Neutralizing antibody titers in immunoglobulin (IG) lots manufactured from pre-pandemic plasma (N=16), plasma of post-COVID-19 individuals (post-COVID,

Neutralizing antibody titers in immunoglobulin (IG) lots manufactured from pre-pandemic plasma (N=16), plasma of post-COVID-19 individuals (post-COVID, N=21), and plasma of mostly COVID-19 vaccinated donors (pandemic, N=18) against (A) SARS-CoV-2, (B) Human Coronavirus NL63 (HCoV-NL63) and (C) HCoV-OC43. Box plots show medians with 25th to 75th percentile ± min/max as whiskers. Geometric mean titers (GMT) are indicated below the x-axis.

Findings

About 363 IG lots were characterized for nAbs against SARS-CoV-2 and HCoVs. None of the IG lots prepared from pre-pandemic donors neutralized SARS-CoV-2. The post-COVID IG exhibited a mean neutralizing activity of 1267 international units (IU) per ml, lower than the mean nAb titers (5122 IU/ml) of pandemic IG lots. In contrast, the pre-pandemic IG neutralized HCoV-OC43 (363 µNT50 geometric mean titer [GMT]) and NL63 (5652 µNT50 GMT). The neutralization of both HCoVs was comparable across the three types of IG preparations.

From September 2020 to October 2021, about 326 IG lots were prepared and screened for nAbs against SARS-CoV-2 and HCoVs. The IG preparations from September 2020 had a mean nAb titer of 2 IU/ml against SARS-CoV-2, which increased to 4210 IU/ml for IG lots prepared in October 2021. Nevertheless, the nAb titers against HCoVs remained relatively stable during this period.

Neutralization of SARS-CoV-2, HCoV-NL63, and HCoV-OC43 by immunoglobulin (IG) released September 2020 – September 2021 (N=326; 13–31 lots / month). SARS-CoV-2 neutralization was normalized to WHO International Standard 20/136 and reported as international units / milliliter (IU/ml). HCoV titers were normalized to an internal standard and reported as µNT50 titer [norm. 1:X]. Shown are geometric mean titer ± 95% confidence intervals.

Neutralization of SARS-CoV-2, HCoV-NL63, and HCoV-OC43 by immunoglobulin (IG) released September 2020 – September 2021 (N=326; 13–31 lots / month). SARS-CoV-2 neutralization was normalized to WHO International Standard 20/136 and reported as international units / milliliter (IU/ml). HCoV titers were normalized to an internal standard and reported as µNT50 titer [norm. 1:X]. Shown are geometric mean titer ± 95% confidence intervals.

Conclusions

Consistent with several other reports, the authors did not observe SARS-CoV-2 neutralization by IG preparations from plasma of pre-pandemic donors. Although post-COVID IG lots potently neutralized SARS-CoV-2, IG preparations from vaccinated donors were nearly 4-fold more potent. The pre-pandemic IG neutralized HCoVs with high potency.

In contrast, post-COVID and pandemic IG lots significantly and potently neutralized SARS-CoV-2. The neutralizing activity of post-COVID and pandemic IG against HCoVs was comparable to that of pre-pandemic IG lots.

The current study's findings suggested that antibody binding or pseudovirus neutralization assay results might not necessarily reflect the neutralization of live viruses.

Notably, plasma from a SARS-CoV-2-infected or vaccinated donor contains both IgG and IgM, while commercial IG preparations only concentrate IgG, which might explain the observed results. The authors posit that IgM might be cross-neutralizing while IgG, despite being cross-reactive between seasonal CoVs and SARS-CoV-2, might not be cross-neutralizing.

This news article was a review of a preliminary scientific report that had not undergone peer-review at the time of publication. Since its initial publication, the scientific report has now been peer reviewed and accepted for publication in a Scientific Journal. Links to the preliminary and peer-reviewed reports are available in the Sources section at the bottom of this article. View Sources

Journal references:

Article Revisions

  • May 13 2023 - The preprint preliminary research paper that this article was based upon was accepted for publication in a peer-reviewed Scientific Journal. This article was edited accordingly to include a link to the final peer-reviewed paper, now shown in the sources section.
Tarun Sai Lomte

Written by

Tarun Sai Lomte

Tarun is a writer based in Hyderabad, India. He has a Master’s degree in Biotechnology from the University of Hyderabad and is enthusiastic about scientific research. He enjoys reading research papers and literature reviews and is passionate about writing.

Citations

Please use one of the following formats to cite this article in your essay, paper or report:

  • APA

    Sai Lomte, Tarun. (2023, May 13). Cross-reactive coronavirus antibodies might not be cross-neutralizing. News-Medical. Retrieved on April 15, 2024 from https://www.news-medical.net/news/20220425/Cross-reactive-coronavirus-antibodies-might-not-be-cross-neutralizing.aspx.

  • MLA

    Sai Lomte, Tarun. "Cross-reactive coronavirus antibodies might not be cross-neutralizing". News-Medical. 15 April 2024. <https://www.news-medical.net/news/20220425/Cross-reactive-coronavirus-antibodies-might-not-be-cross-neutralizing.aspx>.

  • Chicago

    Sai Lomte, Tarun. "Cross-reactive coronavirus antibodies might not be cross-neutralizing". News-Medical. https://www.news-medical.net/news/20220425/Cross-reactive-coronavirus-antibodies-might-not-be-cross-neutralizing.aspx. (accessed April 15, 2024).

  • Harvard

    Sai Lomte, Tarun. 2023. Cross-reactive coronavirus antibodies might not be cross-neutralizing. News-Medical, viewed 15 April 2024, https://www.news-medical.net/news/20220425/Cross-reactive-coronavirus-antibodies-might-not-be-cross-neutralizing.aspx.

Comments

The opinions expressed here are the views of the writer and do not necessarily reflect the views and opinions of News Medical.
Post a new comment
Post

While we only use edited and approved content for Azthena answers, it may on occasions provide incorrect responses. Please confirm any data provided with the related suppliers or authors. We do not provide medical advice, if you search for medical information you must always consult a medical professional before acting on any information provided.

Your questions, but not your email details will be shared with OpenAI and retained for 30 days in accordance with their privacy principles.

Please do not ask questions that use sensitive or confidential information.

Read the full Terms & Conditions.

You might also like...
Research suggests booster doses may be necessary for monkeypox immunity